Diagnosis-to-treatment interval is associated with outcomes in follicular lymphoma treated with immunochemotherapy
Abstract
Abstract A short diagnosis-to-treatment interval independently predicts inferior outcomes in follicular lymphoma. Using international discovery and validation cohorts, we demonstrate its prognostic value beyond established prognostic indices, with implications for risk stratification, clinical trial design, and interpretation.
Article Details
Authors (36)
Prokop Vodička
1First Department of Medicine, First Faculty of Medicine Charles University and General Hospital, Prague, Czech Republic
Tarec Christoffer El-Galaly
3Departments of Hematology, Clinical Epidemiology, and Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark
Vit Prochazka
Christopher R. Flowers
Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine
Diego Villa
8Division of Medical Oncology, BC Cancer Centre for Lymphoid Cancer and The University of British Columbia, Vancouver, Canada
Caroline E. Dietrich
5Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
Lasse H. Jakobsen
4Department of Hematology, Aalborg University Hospital, Aalborg, Denmark
Hervé Ghesquieres
Hopital Lyon Sud, Claude Bernard Lyon 1 University, Pierre-Benite, France
Michael R. Clausen
10Department of Medicine, Vejle Hospital, Vejle, Denmark
Robert Kridel
Princess Margaret Cancer Centre, Toronto
Chan Y. Cheah
12Department of Haematology, Sir Charles Gairdner Hospital, Perth, Australia
Eliza A. Hawkes
14Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Australia
Björn Wahlin
15Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
Maher K. Gandhi
17Translational Research Institute, Mater Research Institute University of Queensland, Brisbane, QLD, Australia
Melissa C. Larson
2Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN
Elliot J. Cahn
2Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN
Jonathan W. Friedberg
18Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY
Peter Martin
Dai Chihara
Jonathon B. Cohen
Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine
Thomas M. Habermann
22Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
Carla Casulo
18Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY
Yucai Wang
State Key Laboratory of Immune Response and Immunotherapy, Department of Radiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine
Peter de Nully Brown
23Department of Hematology, Rigshospitalet, Copenhagen, Denmark
Eric Mou
24Division of Hematology, Oncology, and Blood and Marrow Transplantation, Department of Internal Medicine, University of Iowa, Iowa City, IA
David Belada
4th Department of Internal Medicine - Haematology, University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic
Andrea Janíková
26Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
Heidi Mocikova
Richard Burack
Izidore S. Lossos
29Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
Brad S. Kahl
30Division of Oncology, Washington University School of Medicine, St. Louis, MO
Karin E. Smedby
5Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
Laurie H. Sehn
8Division of Medical Oncology, BC Cancer Centre for Lymphoid Cancer and The University of British Columbia, Vancouver, Canada
Marek Trneny
James R. Cerhan
Matthew J. Maurer
2Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN